AbbVie Agreement And Clinical Trials Will Unlock New Avenues

Published
16 May 25
Updated
16 Aug 25
AnalystConsensusTarget's Fair Value
DKK 540.00
34.3% undervalued intrinsic discount
16 Aug
DKK 355.00
Loading
1Y
-42.7%
7D
1.8%

Author's Valuation

DKK 540.0

34.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on16 Aug 25
Fair value Decreased 15%

The significant downward revision in Gubra’s consensus price target reflects lowered expectations for future growth and earnings, as evidenced by reduced forecasts for both revenue growth and the future P/E multiple, resulting in a new fair value estimate of DKK540. What's in the News Extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) approved at EGM.

Shared on01 Aug 25
Fair value Decreased 15%

Despite a substantial improvement in net profit margin, a sharp reduction in consensus revenue growth forecasts has driven a significant cut in Gubra’s analyst price target from DKK750.00 to DKK635.00. What's in the News Gubra A/S approved an extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) at its EGM.